

ALTG

Australasian Lung Cancer Trials Group



Lung
Foundation
Australia

when you can't breathe... nothing else matters®

Australasian Lung Trials Group 2018 Symposium in Lung Cancer

Sheraton on the Park, Sydney | 6 October, 2018

Proudly sponsored by:



Australian Government
Cancer Australia

Platinum



Gold

AstraZeneca



Silver



Bristol-Myers Squibb

Bronze





Welcome Message

The Australasian Lung Cancer Trials Group (ALTG) welcomes you to the 3rd Symposium in Lung Cancer on the 6th October 2018. For those who have not yet attended an ALTG Symposium, we are sure that this meeting will prove to be a productive and rewarding experience in further understanding the evolution of lung cancer treatment through the latest technology and applications of evidence based research.

We are fortunate to welcome ~~two~~ renowned international speakers; Dr Sanjay Popat, a Consultant Thoracic Medical Oncologist from The Royal

Marsden in London, Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London and current Chair of the British Thoracic Oncology Group (BTOG); Dr Bob Li, a Medical Oncologist from the Memorial Sloan Kettering Cancer Center in New York City specialising in the molecular profile of patients' tumours and leads the clinical research program targeting the HER2 gene in lung cancers; and Mr Chris Draft, Founder, President and CEO of The Chris Draft Family Foundation in Atlanta, Georgia. The Foundation focuses on eight



primary initiatives with overarching themes that stress the importance of education, healthy lifestyles, character development, personal responsibility, self-discipline and physical fitness.

This meeting could not happen without the generous support of educational grants from Cancer Australia, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer Oncology and Roche Oncology. This collaboration is very much appreciated and valued. We have a diverse and fully engaged group of speakers and deserve much praise for being so willing to donate their time and efforts to the meeting. It is a privilege

and pleasure to co-convene the ALTG 2018 Symposium in Lung Cancer.

Best wishes,



A/Prof Nick Pavlakis
ALTG President



Prof Ben Solomon
Scientific Advisory Committee Chair
ALTG Symposium Convenor

Agenda

Saturday 6th October, 2018

Topic	Speaker	Time
Roche Breakfast Symposium	An update on immunotherapy in Small Cell Lung Cancer care - Including panel discussion and Q&A Speakers: Dr Sanjay Popat & Prof Ben Solomon Chair: Prof Stephen Clarke	07.00 - 08.00
Welcome/opening	Prof Ben Solomon	08.30 - 08.45
Lung Cancer Today The Consumer's Perspective	Mr Chris Draft	08.45 - 09.05
Immunotherapy		09.05 - 10.10
PLENARY 1 Immunotherapy in Non-Small Cell Lung Cancer - What to use, in whom and when?	Dr Sanjay Popat	09.05 - 09.50
Pathology Report (PDL1 & TMB)	A/Prof Wendy Cooper	09.50 - 10.10
Break		10.10 - 10.35
Targeted therapy in Non-Small Cell Lung Cancer (NSCLC)		10.35 - 12.50
PLENARY 2 New targets and blood testing	Dr Bob Li	10.35 - 11.20
EGFR Mutated NSCLC- latest data	A/Prof Tom John	11.20 - 12.05
ALK Rearranged NSCLC - update and new directions	Dr Malinda Itchins	12.05 - 12.50
Lunch		12.50 - 13.40
Mesothelioma		13.40 - 14.40
Mesothelioma - where are we now?	A/Prof Nick Pavlakis	13.40 - 14.00
ALTG DREAM Trial and future directions	Prof Anna Nowak	14.00 - 14.20
Advanced NSCLC - new treatment paradigm - how to use immunotherapy? - QA Dr Sanjay Popat, Dr Bob Li, Mr Chris Draft, Prof Ben Solomon, A/Prof Tom John & A/Prof Nick Pavlakis	Chair: Prof Michael Boyer	14.20 - 15.15
Symposium closing	Prof Ben Solomon & A/Prof Nick Pavlakis	15.15 - 15.30
Closing (followed by afternoon tea break)		15.30 - 16.00

Organising Committee

A/Prof Nick Pavlakis



A/Prof Nick Pavlakis is a medical oncologist with 20 years of experience in the field of oncology, clinical and translational research, with a special interest in the development of new cancer drugs. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001. A/Prof Nick Pavlakis is current Chair of the Lung Cancer Group of the Clinical Oncologic Society for Australia (COSA), and is Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC). He is conducting ongoing collaborative clinical research with the Australasian Gastro-intestinal Trials Group (AGITG), ALTG as a President, Australia and NZ Urologic and Prostate Cancer Trials Group (ANZUP) and translational research with the Bill Walsh Cancer Research Laboratories/Kolling Institute.

Prof Ben Solomon



Prof Ben Solomon is a medical oncologist in the Lung Service and the Head and Neck service. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He completed a PhD investigating

the mechanisms by which EGFR inhibition enhance the effects of radiation, and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors. Prof Solomon practices as a medical oncologist with a research focus on clinical and translational research in lung cancer and head and neck cancer at Peter MacCallum Cancer Centre. His clinical trial work focuses on the identification of novel therapies for lung cancer.

Lillian Leigh



Lillian Leigh is a Sydney lawyer, wife and mother who lives with lung cancer. For over a decade as a consumer advocate, Lillian provided legal services to

disadvantaged people in Australia. When she was diagnosed in her early 30's with a rare lung cancer, advocacy for lung and rare cancers became her new passion. Lillian is a consumer member of Cancer Australia's Priority-driven Collaborative Cancer Research Scheme (PdCCRS) Grant Review Committee, the Australasian Lung cancer Trials Group, and Lung Foundation Australia's Patient Advisory Committee. She is also a volunteer advocate for Rare Cancers Australia and Cancer Council NSW. In December 2016, Lillian received a Patient Advocacy Award at the 17th World Conference on Lung Cancer Conference in Vienna.

Organising Committee

Dr Chee Lee



Dr Chee Khoon Lee is a consultant medical oncologist, and a staff specialist at the St George Hospital and the Sutherland Hospital. He obtained his

PhD from the University of Sydney in 2012 for his methodological work in the conduct of clinical trials involving biomarkers for personalising treatment in patients with advanced cancers. He is the Director of the Clinical Research Unit (Medical Oncology) at St George Hospital. He actively enrolls patients into clinical studies that investigate novel therapeutic agents in lung, ovarian, and breast cancers.

Dr Emily Stone




Dr Stone is a graduate of the University of Sydney and practices as a Staff Specialist Thoracic Physician at St Vincent's Hospital Sydney and is Chair and founder of the St

Vincent's Lung Cancer Multidisciplinary Team at the Kinghorn Cancer Centre. She has subspecialty interests in clinical lung cancer care, the effect of multidisciplinary team care on lung cancer outcomes and on the impact of tobacco control policies on respiratory health. Dr Stone

runs a specialist Lung Cancer Clinic at the Kinghorn Cancer Centre at St Vincent's Hospital, participates in clinical lung cancer trials at both Principal and Co-Investigator levels and collaborates in translational research across multiple institutions. She holds a number of executive and committee positions including Head Elect, Thoracic Oncology Assembly of the Asian Pacific Society of Respirology, member of the IASLC Tobacco Control Committee, member of the Program Committee for WCLC 2018 and is an Associate Editor for the Journal of Thoracic Oncology.

Dr Steven Kao



Dr Steven Kao is a medical oncologist at the Chris O'Brien Lifehouse, Camperdown. He completed his PhD at the ADRI and focused his research

on predictive and prognostic factors in malignant mesothelioma. Steven has a wide clinical, translational and psychosocial research interest in thoracic cancers including malignant mesothelioma and asbestos-related lung cancers. He was awarded the Premier's Award for Outstanding Cancer Research Scholar from the Cancer Institute NSW in 2012.

Sue McCullough



Consumer Advisory Committee (CAC) member Sue McCullough has been a voice for cancer patients and their families for nearly 15 years. After being

diagnosed with lung cancer in 2003, Sue saw first-hand that there was a lack of support services for lung cancer patients within the health care system. Instead, she said, clinicians were focused solely on getting patients to stop smoking.

Sara McLaughlin-Barrett



Sara McLaughlin-Barrett is a Lung Clinical Nurse Consultant at Monash Health. She has extensive experience with lung cancer and mesothelioma

patients across all modalities of care (respiratory, thoracic surgery, medical oncology, radiation oncology and palliative care). Sara has worked in both the public and private sector as a Lung CNC. Sara was the project manager for the Victorian Lung Cancer Redesign Project for Monash Health in 2016/2017. She has a passion for improving healthcare services and decreasing delays to treatment.

A/Prof Paul Mitchell



A/Prof Paul Mitchell holds the positions of medical oncologist at the Olivia Newton-John Cancer and Wellness Centre at Austin Health in Melbourne, Director of

the North-Eastern Melbourne Integrated Cancer Service (Cancer Network), and is an associate professor at the University of Melbourne. Dr Mitchell was President of the Australasian Lung Cancer Trials Group (ALTG) 2012-2016 and has been involved in clinical and laboratory research for over 20 years. He is Chairman of the Thoracic Alliance for Cancer Trials (TACT) which brings together national and trans-national lung cancer trials groups. He also sits on the State Government Cancer Quality and Outcomes Committee and the Program Assessing Committee of the Health Research Council of New Zealand.

International Speakers

Dr Sanjay Popat



Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.

Sanjay qualified from Guy's and St Thomas' Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.

He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.

He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).

Dr Bob Li



Dr Bob T. Li, MD, MBBS, MPH, FRACP, is an attending medical oncologist at the Thoracic Oncology and Early Drug Development Service, Memorial

Sloan Kettering Cancer Center in New York, United States. Bob completed his medical degree at the University of New South Wales in Sydney, Australia, and postgraduate training under the Royal Australasian College of Physicians. He has completed medical oncology fellowships at Royal North Shore Hospital and Memorial Sloan Kettering Cancer Center (MSK), before being appointed to the faculty at MSK.

As principle investigator and physician-scientist of the Early Phase Drug Development Program at MSK, Bob leads numerous phase I and II basket trials of new cancer medicines targeting HER2 and the MAPK pathways. His translational research in the HER2 oncogene has led to the completion of the first positive clinical trial in patients with HER2-mutant lung cancers, which has already changed the 2018 NCCN Clinical Practice Guidelines for non-small cell lung cancer. Bob also leads the MSK Thoracic Liquid Biopsy Program investigating the use of plasma circulating tumor DNA analysis as a non-invasive technology to capture genomic evolution of lung cancers and optimize precision therapy. Bob has received awards from the American Society of Clinical Oncology and the American Association for Cancer Research for his research, and has numerous scientific publications in prestigious journals such as *Nature*, *Nature Medicine*, *Cancer Discovery*, and *Journal of Clinical Oncology*.

As an Australian oncologist practicing in the United States, Bob is particularly keen on establishing and building an international collaboration between MSK and ALTG to advance the science toward conquering lung cancers.

Mr Chris Draft



Mr Chris Draft is the Founder, President and CEO of the Chris Draft Family Foundation located in Atlanta, Georgia. The Foundation's mission has been to

empower families to lead healthy lifestyles. He is also the Co-Founder of Team Draft, leading the creation of a national campaign that is changing the face of lung cancer. He is an internationally recognized speaker, community leader, and family and character advocate who serves as an National Football League Ambassador and spokesperson on many health-related issues, including the care and treatment of asthma, from which he suffers, and lung cancer, the disease that claimed the life of his wife, Keasha in 2011.

Bristol-Myers Squibb is pioneering research to identify potential tumour and immune biomarkers to help match the **right patient** with the **right treatment** at the **right time**.



Bristol-Myers Squibb



Immuno-Oncology

© 2018 Bristol-Myers Squibb. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3170. IOAU1805201. Date of preparation: September 2018. BRMSCH0487.

KEYTRUDA®

(pembrolizumab)

Before prescribing,
please review the Product
Information.

Product information is
available at www.msinfo.com.au/keytrudapi

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. ONCO 1270259-0000. First issued September 2018. ONC1282.



MSD

PBS Information: KEYTRUDA is not listed on the PBS for NSCLC.

AstraZeneca 

What science can do

AstraZeneca Pty. Ltd.
ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113.
www.astrazeneca.com.au. For Medical Information enquiries: 1800 805 342 or medinfo.australia@astrazeneca.com. To report an adverse event: 1800 805 342 or via <https://aereporting.astrazeneca.com>. AU-5041. WL299000. September 2018



AN EFFECTIVE OPTION IS NOW PBS LISTED IN 2ND-LINE NSCLC^{1-4*}

*Median overall survival superior to docetaxel (ITT850): 13.8 vs 9.6 months, $p=0.0006$.²⁻⁴

Streamlined listing for the
treatment of locally advanced
(stage IIIB) or metastatic
(stage IV) NSCLC with
progression on or after
prior chemotherapy¹

NSCLC, non-small cell lung cancer; ITT850, OAK trial primary intent to treat (ITT) population.

PBS Information: Authority required (STREAMLINED).
Refer to PBS Schedule for full authority information.

Please review Product Information before prescribing, available at
www.roche-australia.com/productinfo/tecentriq

References: 1. Department of Health, Pharmaceutical Benefits Scheme. Available at: www.pbs.gov.au 2. TECENTRIQ Approved Product Information. Available at: www.roche-australia.com/productinfo/tecentriq 3. Rittmeyer A *et al. Lancet* 2017;389:255–265. 4. Fehrenbacher L *et al. J Thorac Oncol* 2018;13:1156–1170. Further information is available on request from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney NSW 2000. Medical Information: 1800 233 950. ®Registered Trademark EMVTEC0154 MN37563766 Prepared Sep18

ALTG 2018 Symposium in Lung Cancer

Proudly hosted by:



Proudly sponsored by:



Australian Government
Cancer Australia

Platinum



Gold



Silver



Bronze



Level 2, 11 Finchley Street,
Milton, QLD 4064

PO Box 1949, Milton, QLD 4064

altg@lungfoundation.com.au

lungfoundation.com.au

1800 654 301



**Lung
Foundation
Australia**

when you can't breathe... nothing else matters®